Glenmark Pharmaceuticals Receives FDA Approval for Fluticasone Propionate Nasal Spray USP (OTC)
Elmwood Park, New Jersey, March 19, 2026 – Glenmark Pharmaceuticals Limited (Glenmark) announced it has received final approval from the United States Food & Drug Administration (U.S. FDA) for Fluticasone Propionate Nasal Spray USP, 50 mcg per spray (OTC). Glenmark’s product has been determined by the FDA to be bioequivalent to Flonase® Allergy Relief Nasal Spray, 50 mcg per spray, of Haleon US Holding LLC [NDA 205434] and will be distributed in the U.S. by Glenmark Therapeutics Inc., USA.According to Nielsen® syndicated data for the 52-week period ending March 3, 2026, the Flonase® Allergy Relief Nasal Spray market achieved annual sales of...